(Q40648026)

English

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

scientific article published on July 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 September 2017

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group (English)

1 reference

Europe PubMed Central

22 September 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

10

object named as

Blazar BR

1 reference

Europe PubMed Central

22 September 2017

author name string

Frost JD

1

1 reference

Europe PubMed Central

22 September 2017

Hank JA

2

1 reference

Europe PubMed Central

22 September 2017

Reaman GH

3

1 reference

Europe PubMed Central

22 September 2017

Frierdich S

4

1 reference

Europe PubMed Central

22 September 2017

Seeger RC

5

1 reference

Europe PubMed Central

22 September 2017

Gan J

6

1 reference

Europe PubMed Central

22 September 2017

Anderson PM

7

1 reference

Europe PubMed Central

22 September 2017

Ettinger LJ

8

1 reference

Europe PubMed Central

22 September 2017

Cairo MS

9

1 reference

Europe PubMed Central

22 September 2017

Krailo MD

11

1 reference

Europe PubMed Central

22 September 2017

Matthay KK

12

1 reference

Europe PubMed Central

22 September 2017

Reisfeld RA

13

1 reference

Europe PubMed Central

22 September 2017

Sondel PM

14

1 reference

Europe PubMed Central

22 September 2017

language of work or name

0 references

publication date

1 July 1997

1 reference

Europe PubMed Central

22 September 2017

1 reference

Europe PubMed Central

22 September 2017

80

1 reference

Europe PubMed Central

22 September 2017

2

1 reference

Europe PubMed Central

22 September 2017

317-333

1 reference

Europe PubMed Central

22 September 2017

Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C317%3A%3AAID-CNCR21%3E3.0.CO%3B2-W

21 January 2018

Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C317%3A%3AAID-CNCR21%3E3.0.CO%3B2-W

21 January 2018

The cellular immunotherapy of cancer: current and potential uses of interleukin-2.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C317%3A%3AAID-CNCR21%3E3.0.CO%3B2-W

21 January 2018

A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C317%3A%3AAID-CNCR21%3E3.0.CO%3B2-W

21 January 2018

Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C317%3A%3AAID-CNCR21%3E3.0.CO%3B2-W

21 January 2018

Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C317%3A%3AAID-CNCR21%3E3.0.CO%3B2-W

21 January 2018

Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C317%3A%3AAID-CNCR21%3E3.0.CO%3B2-W

21 January 2018

Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C317%3A%3AAID-CNCR21%3E3.0.CO%3B2-W

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C317%3A%3AAID-CNCR21%3E3.0.CO%3B2-W

21 January 2018

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C317%3A%3AAID-CNCR21%3E3.0.CO%3B2-W

21 January 2018

A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819970715%2980%3A2%3C317%3A%3AAID-CNCR21%3E3.0.CO%3B2-W

21 January 2018

Identifiers

10.1002/(SICI)1097-0142(19970715)80:2<317::AID-CNCR21>3.0.CO;2-W

1 reference

Europe PubMed Central

22 September 2017

1 reference

Europe PubMed Central

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40648026&oldid=1904117174"